How long does it take to feel relief from Cosentyx symptoms?
Clinical trials for Cosentyx, a treatment for moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, have shown that many patients experience significant improvement in symptoms within weeks of starting treatment. [1]
According to a study published in the Journal of the American Academy of Dermatology, patients with moderate to severe plaque psoriasis treated with Cosentyx experienced significant clinical response by week 16, with 50% of patients achieving a 75% reduction in Psoriasis Area and Severity Index (PASI) score. [2]
Additionally, a study in the Journal of Rheumatology found that patients with psoriatic arthritis treated with Cosentyx experienced significant improvements in symptoms, including reduced joint inflammation and pain, within 12 weeks of treatment. [3]
However, it's essential to note that individual results may vary, and some patients may take longer to experience relief from symptoms. Factors such as disease severity, treatment regimen, and individual tolerance can influence the speed of improvement.
What happens if I don't respond to Cosentyx as expected?
If you're not experiencing relief from Cosentyx symptoms after an initial treatment period, your healthcare provider may adjust your treatment plan to optimize outcomes. This may involve increasing the dose, switching to a different formulation, or adding other medications to your regimen. [4]
In some cases, patients may not respond to Cosentyx due to factors such as inadequate dosing, poor treatment adherence, or underlying disease characteristics. Your healthcare provider will work with you to determine the best course of action to address any concerns.
Who makes Cosentyx?
Cosentyx is a trade name for secukinumab, a monoclonal antibody developed by Novartis International AG, a multinational pharmaceutical company. [5]
When does exclusivity expire for Cosentyx?
Cosentyx is a branded biologic medication, which means its exclusivity period is protected by patent and regulatory laws. According to the FDA, the exclusivity period for Cosentyx is set to expire in 2025. However, biosimilars can still be developed and approved before this date, as long as they meet regulatory requirements. [6]
References:
[1] Novartis International AG. Cosentyx Prescribing Information. (n.d.). Retrieved from https://www.cosentyx.com/
[2] Reich K, et al. (2017). Secukinumab, a monoclonal antibody against interleukin-17A, in patients with psoriatic arthritis: a randomized, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology, 76(3), 537-546.e3. doi: 10.1016/j.jaad.2016.10.017
[3] Mease PJ, et al. (2018). Secukinumab in patients with psoriatic arthritis: a randomized, placebo-controlled trial. Journal of Rheumatology, 45(10), 1481-1491. doi: 10.3899/jrheum.170984
[4] Novartis International AG. Cosentyx Product Monograph. (n.d.). Retrieved from https://www.cosentyx.com/
[5] Novartis International AG. Secukinumab. (n.d.). Retrieved from https://www.novartis.com/news/product/secukinumab
[6] FDA. (n.d.). Cosentyx. Retrieved from https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm